1. Home
  2. PTLO vs CAPR Comparison

PTLO vs CAPR Comparison

Compare PTLO & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Portillo's Inc.

PTLO

Portillo's Inc.

HOLD

Current Price

$5.27

Market Cap

433.0M

ML Signal

HOLD

Logo Capricor Therapeutics Inc.

CAPR

Capricor Therapeutics Inc.

HOLD

Current Price

$30.37

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PTLO
CAPR
Founded
1963
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
433.0M
1.3B
IPO Year
2021
2011

Fundamental Metrics

Financial Performance
Metric
PTLO
CAPR
Price
$5.27
$30.37
Analyst Decision
Hold
Strong Buy
Analyst Count
11
8
Target Price
$8.06
$41.38
AVG Volume (30 Days)
1.4M
1.1M
Earning Date
05-28-2026
06-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.27
N/A
Revenue
$732,066,000.00
$22,270,465.00
Revenue This Year
$9.07
N/A
Revenue Next Year
$6.31
$17,308.50
P/E Ratio
$19.11
N/A
Revenue Growth
3.03
N/A
52 Week Low
$4.41
$4.30
52 Week High
$13.55
$40.37

Technical Indicators

Market Signals
Indicator
PTLO
CAPR
Relative Strength Index (RSI) 48.52 58.57
Support Level $4.51 $25.33
Resistance Level $5.30 $40.37
Average True Range (ATR) 0.29 1.88
MACD -0.02 0.50
Stochastic Oscillator 38.40 47.91

Price Performance

Historical Comparison
PTLO
CAPR

About PTLO Portillo's Inc.

Portillos Inc serves the Chicago street food industry through high-energy and multichannel restaurants designed to ignite the senses and create memorable dining experiences. It owns and operates fast-casual restaurants in the United States, along with two food production commissaries in Illinois. Its menu includes hot dogs, beef and sausage sandwiches, sandwiches and ribs, salads, burgers, chicken, Barnelli's pasta, sides and soup, and desserts and shakes.

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Share on Social Networks: